脂蛋白a在动脉粥样硬化性心血管疾病中的临床研究进展  

Advances in clinical research on lipoprotein a in atherosclerotic cardiovascular diseases

作　　者：娄奇 王红[1] 刘广忠(综述)[1] 李为民(审校)[1] LOU Qi;WANG Hong;LIU Guang-zhong(Department of Cardiovascular Medicine,the First Affiliated Hospital of Harbin Medical University,Heilongjiang 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院心血管内科,黑龙江150001

出　　处：《中国临床新医学》2023年第1期91-96,共6页CHINESE JOURNAL OF NEW CLINICAL MEDICINE

基　　金：黑龙江省自然科学基金项目(编号:LH2021H042)。

摘　　要：脂蛋白a[Lp(a)]水平的升高是冠状动脉疾病、脑卒中、外周动脉疾病及钙化性主动脉瓣狭窄等动脉粥样硬化性心血管疾病(ASCVD)的独立危险因素。有研究证实,即使将低密度脂蛋白胆固醇水平控制在理想范围内,高Lp(a)水平仍然会增加ASCVD的风险。该文从Lp(a)及其致病机制、Lp(a)水平与ASCVD的关系、高Lp(a)血症的治疗等作一综述。The elevated level of lipoprotein a[Lp(a)]is an independent risk factor for atherosclerotic cardiovascular diseases(ASCVD),such as coronary artery disease(CAD),stroke,peripheral arterial disease and calcific aortic valve stenosis(CAVS).Studies have confirmed that the high levels of Lp(a)increase the risk of ASCVD even when the levels of low-density lipoprotein cholesterol(LDL-C)are kept within the ideal range.This paper reviews Lp(a)and its pathogenic mechanism,the relationship between Lp(a)level and ASCVD,and the treatment of high Lp(a)level in the blood.

关 键 词：脂蛋白A 动脉粥样硬化性心血管疾病 临床研究进展 

分 类 号：R684.3[医药卫生—骨科学]